kidney cancer

Pharma

Merck's Welireg again comes up short in OS but excels in PFS

Merck’s Welireg continues to show benefits in PFS but no significant improvement in overall survival when compared to Novartis’ chemotherapy Afinitor.

Kevin Dunleavy Sep 13, 2024 8:00am

BMS' Opdivo, Aveo's Fotivda fail as combo in kidney cancer

Jul 18, 2024 4:26pm

ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC

May 23, 2024 5:00pm

BMS touts latest Opdivo data as I-O battle heads to new front

Jan 29, 2024 8:45am

Merck celebrates trial win, while Bristol fails in kidney cancer

Jan 27, 2024 10:00am

FDA signs off on 2nd approval for Merck's Welireg

Dec 15, 2023 11:33am